Enhanced Therapeutic Benefits of Combined Metformin and Curcumin in Women with Polycystic Ovary Syndrome: Results from a Factorial Clinical Trial
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health Specialties

Enhanced Therapeutic Benefits of Combined Metformin and Curcumin in Women with Polycystic Ovary Syndrome: Results from a Factorial Clinical Trial

A 12-week randomized trial demonstrates that combining metformin and nanocurcumin significantly improves lipid metabolism, glucose regulation, hormonal balance, and body metrics in women with PCOS, surpassing effects seen with either agent alone or placebo.
Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial
Posted inClinical Updates OB/GYN & Women's Health Oncology Specialties

Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial

This phase II study shows that adding metformin to standard chemoradiotherapy in locally advanced cervical cancer is safe, well tolerated, and feasible, with no significant increase in severe adverse events and successful biomarker-based tumor hypoxia assessments.
Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial
Posted inOB/GYN & Women's Health Oncology Specialties

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm, highlighting the need for alternative therapeutic strategies.
Vitamin D3 as a Potential Therapeutic Agent in Polycystic Ovary Syndrome: Insights from a Prospective Double-Blind Randomized Trial
Posted inClinical Updates Family Medicine & Nutrition news OB/GYN & Women's Health Specialties

Vitamin D3 as a Potential Therapeutic Agent in Polycystic Ovary Syndrome: Insights from a Prospective Double-Blind Randomized Trial

A recent double-blind randomized controlled trial demonstrates that weekly supplementation with vitamin D3 significantly improves ovarian morphology, menstrual regularity, and ovulation rates in women with PCOS, suggesting a role as standalone or adjunctive therapy.